Ambrx Biopharma — Investor Presentation (November 2021)
31 slides from Ambrx Biopharma's investor presentation, Nov 8, 2021
Slide 1: Precision Biologics for Life
Precision Biologics for Life NYSE: AMAM November 2021 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements © 2021 Ambrx Biopharma Inc. All rights reserved Certain statements contained in this presentation, other than statements of historical fact, are "forward-looking" statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statem
Slide 3: Leadership
Leadership Feng Tian, Ph.D. CEO & President Joy Yan, M.D., Ph.D. CMO Simon Allen, MBA CBO Executive Leadership Team Sonja Nelson, CPA CFO Shawn Zhang, Ph.D. SVP, R&D Operations Scientific Advisory Board Peter Schultz Melissa Starovasnik Stuart Lutzker Jakob Dupont Luisa Salter-Cid Feng Tian © 2021 A
Slide 4: Company Overview
Company Overview Proprietary technology platform with broad and long-lasting IP protection Lead asset ARX788 (HER2 ADC) in three pivotal trials with a defined path to commercialization FDA Fast Track and China NMPA Breakthrough Therapy Designations for breast cancer and FDA Orphan Drug Designation f
Slide 5: Internal Pipeline
Internal Pipeline © 2021 Ambrx Inc. All rights reserved Candidate Indications Trial Setting (Name) Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone(s) Ambrx Rights ADC Oncology ARX788 Anti-HER2 ADC HER2+ mBC (FDA granted Fast Track Designation and NMPA granted Breakthrough Designation
Slide 6: Our Proprietary Platforms and Technologies
Our Proprietary Platforms and Technologies
Slide 7: Ambrx Technology Designed to Overcome Limitations of Natural Proteins
Ambrx Technology Designed to Overcome Limitations of Natural Proteins and Greatly Enhance Protein Therapeutics Using E.coli to produce simple and single domain proteins; without post-translation modifications; scaled up to 50,000 L Broad Collection of Payloads: Cytotoxic agents Immune stimulators PK
Slide 8: Versatility and Breakthrough Nature of Our Platform
The Versatility and Breakthrough Nature of Our Platform Is Demonstrated By Ability to Generate Novel Product Candidates Antibody-Drug Conjugates ARX-788 Bi-specifics aCD3-folate Broad, Pioneering, and Dominant IP Positions Expanded genetic code creates engineered proteins by site-specifically incorp
Slide 9: Expanding the Genetic Code and Enabling New Chemistry and Site-Specific Conjugation
Continuing the Biotech Revolution: Expanding the Genetic Code and Enabling New Chemistry and Site-Specific Conjugation © 2020 Ambrx Inc. All rights reserved 2 Conventional Conjugates POC that conjugations work and can support billion-dollar drugs Typically relies on lysines and cysteines for conjuga
Slide 10: ARX788: Site-Specific ADC for Breast, Gastric, and HER2 Cancers
ARX788: Site-Specific ADC for Breast, Gastric, and HER2-expressing or HER2-mutated Cancers The Design: Potential Advantages: Overcome the stability limitations commonly found in conventional conjugation techniques Minimize off-target toxicity caused by premature detachment of the cytotoxic payload i
Slide 11: Lead Clinical Program: ARX788 Anti-HER2 ADC
Lead Clinical Program: ARX788 Anti-HER2 ADC
Slide 12: ARX788 Clinical Studies Overview
Study No. Phase Brief Description Region Study Status ACE-Pan Tumor-01 Phase 1 Dose escalation and cohort expansion (including HER2-low breast) in various tumors with HER2 Overexpression (N=160) US and Australia Ongoing ACE-Breast-01 Phase 1 Dose escalation and cohort expansion in HER2-positive Brea
Slide 13: Ongoing ACE-Breast-01 and ACE-Pan-Tumor-01 Trials
Ongoing ACE-Breast-01 and ACE-Pan-Tumor-01 Trials ACE-Breast-01 ACE-Pan-Tumor-01 Phase 1a Dose Escalation Dose Level (N: Response Evaluable) Confirmed ORR DCR Dose Level (N: Response Evaluable) Confirmed ORR DCR 0.33 & 0.66 mg/kg (N=6) 0% 83% 0.66 mg/kg (N=5) 20% 60% 0.88 mg/kg (N=7) 14% 86% 0.88 mg
Slide 14: ARX788: Deep Response in ACE-Breast-01
ARX788: Deep Response in ACE-Breast-01 (1.3 and 1.5 mg/kg Cohorts) Presented at ASCO 2021 Data cut-off: Apr-07-2021 © 2021 Ambrx Biopharma Inc. All rights reserved
Slide 15: ARX788 Rapid, Deep and Durable Response in ACE-Breast-01
ARX788 Showed Rapid, Deep and Durable Response in ACE-Breast-01 (1.3 and 1.5 mg/kg cohort) Presented at ASCO 2021 Data cut-off: Apr-07-2021 © 2021 Ambrx Biopharma Inc. All rights reserved
Slide 16: Clinical Efficacy (Ongoing ACE-Gastric-01 Trial)
Clinical Efficacy (Ongoing ACE-Gastric-01 Trial) ACE-Gastric-01 Dose Level (N: Response Evaluable) ORR DCR 1.3 mg/kg (N=7)* 42.9% 57.1% 1.5 mg/kg (N=13) 46.2% 46.2% 1.7 mg/kg (N=7) 42.9% 85.7% All (N=27) 44.4% 59.3% Presented at CSCO 2021 Data cut-off: Jun-30-2021 *Two subjects are conside
Slide 17: Summary of ARX788 Safety Data (All Cohorts)
Summary of ARX788 Safety Data (All Cohorts) ARX788 (All Treated Population) Number of patients (%) ACE-Breast-01 (N=69) ACE-Pan-Tumor-01 (N=49) ACE-Gastric-01 (N=30) All AEs (regardless of causality) 69 (100%) 44 (89.8%) 30 (100%) Drug-related AEs (any grade) 67 (97.1%) 38 (77.6%) 28 (93.3%) All AE
Slide 18: Systemic Toxicity: ARX788 (All Cohorts)
Systemic Toxicity: ARX788 (All Cohorts) Data cut-off: Jun-30-2021 for ACE-Breast-01, Jul-14-2021 for ACE-Gastric-01, Jul-12-2021 for ACE-Pan-Tumor-01 ARX788 (All Treated Population) Number of patients (%) Enhertu (5.4 mg/kg)* Number of patients (%) ACE-Breast-01 (N=69) ACE-Pan-Tumor-01 (N=49) ACE-Ga
Slide 19: Adverse Events of Special Interest (All Cohorts)
Adverse Events of Special Interest (All Cohorts) *Included one subject from ACE-Pan tumor-01 study with event terms updated from dry eye and eye discomfort to ocular surface disease **Included verbatim term of corneal epithelial injury Data Cut-off : Jun-30-2021 for ACE-Breast-01, Jul-14-2021 for AC
Slide 20: Summary of ARX788 Clinical Trials
Summary of ARX788 Phase 1 Clinical Trials Clinical response in heavily pre-treated patients whose disease is resistant/refractory to other HER2 targeted regimens (including HER2 ADC and HER2 bi-specifics) Unique PK profiles (low serum payload exposure) ü ü mDOR of 14.4 months and 12.9 months for ACE
Slide 21: Case Study: Brain Met Completely Resolved in ACE-Pan-Tumor-01
Case Study: Observed Brain Met Completely Resolved in the ACE-Pan-Tumor-01 Trial Baseline Brain Met Confirmed PR for a U.S. breast cancer patient with HER2 IHC1+/FISH+ Liver and brain metastases Brain lesion completely resolved after 8 cycles at 0.66 mg/kg (see red circle on CT) Completely Resolved
Slide 22: Additional Treatment Settings: HER2-Low and Combination Models
Additional Treatment Settings: Strong Anti-tumor Activity in HER2-Low and Synergistic Effects in Combo Cancer Models 10 20 30 40 50 0 500 1000 1500 2000 Effect of ARX788 + anti-PD-1 on JMT-1 Breast Cancer Model Days After Inoculation T u m o r V o l u m e ( m m 3 ) Control ARX788 1mg/kg anti-PD-1 3m
Slide 23: ARX788 Development Strategy
ARX788 Development Strategy: Accelerate Development with Plan to Expand Into Additional Indications and Tumor Types Large market opportunities Accelerate development and expand into other tumor types Long-term: Penetrate into earlier lines and adjuvant/neoadjuvant settings ACE-Breast-02 (China): Piv
Slide 24: Highlight of Pipeline Programs
Highlight of Pipeline Programs
Slide 25: ARX517 (anti-PSMA ADC) for mCRPC
ARX517 (anti-PSMA ADC) – Promising ADC for mCRPC and PSMA Expressing Tumors Potential for treating PSMA over-expressed cancer such as prostate cancer, especially in metastatic castration-resistant prostate cancer (mCRPC) Potent in vivo anti-tumor demonstrated in both enzalutamide sensitive and resis
Slide 26: ARX102 (Smart IL-2)
ARX102 (Smart IL-2) Designed to Stimulate Immune System by Targeting β and γ (While Sparing α) Receptors on T Cell ARX102 Increased CD8+ in Tumor Site (CT26 Model) Vehicle ARX102 (3mg/kg) Dose-response Activity of ARX102 in E0771 Syngeneic Breast Cancer Model Precision-engineered Smart IL-2 molecule
Slide 27: ARX822 (Anti-CD3-Folate Bispecific)
ARX822 (Anti-CD3-Folate Bispecific) Has Demonstrated Strong Anti-tumor Activities Against Ovarian Cancer and TNBC Models Activity of ARX822-Related CD3-Folate Bispecifics in TNBC (CAL51) Model Activity of ARX822-Related CD3-Folate Bispecifics in Carboplatin-Resistant Ovarian (OV-90) Cancer Model ARX
Slide 28: Ambrx Immune Stimulating Antibody Conjugate (ISAC) Programs
Ambrx Immune Stimulating Antibody Conjugate (ISAC) Programs Dose-response Activity of TAA1 ISAC in Syngeneic Tumor Model TAA1-ISAC Exhibits Durable Anti-Tumor Immunity: Re-challenging study in MC38 Model Precision-engineered ISACs are designed to address issues observed with earlier generations of I
Slide 29: Summary
_OMBRA | Summary AMBRX
Slide 30: Partnering Strategy
Partnering Strategy Late-Stage Programs that have secured human POC Select partner for global clinical, regulatory and commercial expertise and availability of products for combination therapy Geographic Programs that benefit from a regional partner Countries have different disease prevalence, regul
Slide 31: Company Overview
Company Overview Proprietary technology platform with broad and long-lasting IP protection Lead asset ARX788 (HER2 ADC) in three pivotal trials with a defined path to commercialization FDA Fast Track and China NMPA Breakthrough Therapy Designations for breast cancer and FDA Orphan Drug Designation f
Ambrx Biopharma — Investor Presentation (November 2021) on 6ix